| Species |
Human |
| Protein Construction |
| hFc |
NRG1 Beta 1 (Ser2-Lys246)_x000D_
Accession # Q02297-6 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Her4, His Tag at 2μg/ml (100μl/well) on the plate can bind NRG1 Beta 1 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
54.00 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Neuregulin-1 (NRG-1) is a ligand of the epidermal growth factor receptor (erbB), and its interaction involves activation of the glutamatergic N-methyl-Daspartate receptor, which increases the expression of the β2 subunit of the γ- aminobutyric acid receptor and subunits of the nicotinic acetylcholine receptor. |
| Synonyms |
Pro-NRG1; NRG1; GGF; HGL; HRGA; NDF; SMDF; Beta1; Beta1A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
